HomeCompareVCON vs ABBV

VCON vs ABBV: Dividend Comparison 2026

VCON yields 3.08% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $78.0K in total portfolio value
10 years
VCON
VCON
● Live price
3.08%
Share price
$65.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.4K
Annual income
$375.14
Full VCON calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VCON vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVCONABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VCON + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VCON pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VCON
Annual income on $10K today (after 15% tax)
$261.54/yr
After 10yr DRIP, annual income (after tax)
$318.87/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,737.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VCON + ABBV for your $10,000?

VCON: 50%ABBV: 50%
100% ABBV50/50100% VCON
Portfolio after 10yr
$63.3K
Annual income
$12,573.45/yr
Blended yield
19.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VCON
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VCON buys
0
ABBV buys
0
No recent congressional trades found for VCON or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVCONABBV
Forward yield3.08%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$24.4K$102.3K
Annual income after 10y$375.14$24,771.77
Total dividends collected$3.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VCON vs ABBV ($10,000, DRIP)

YearVCON PortfolioVCON Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,008$307.69$11,550$430.00$542.00ABBV
2$12,095$316.54$13,472$627.96$1.4KABBV
3$13,266$325.05$15,906$926.08$2.6KABBV
4$14,528$333.21$19,071$1,382.55$4.5KABBV
5$15,886$341.03$23,302$2,095.81$7.4KABBV
6$17,347$348.51$29,150$3,237.93$11.8KABBV
7$18,917$355.66$37,536$5,121.41$18.6KABBV
8$20,603$362.48$50,079$8,338.38$29.5KABBV
9$22,415$368.97$69,753$14,065.80$47.3KABBV
10$24,359$375.14$102,337$24,771.77$78.0KABBV

VCON vs ABBV: Complete Analysis 2026

VCONStock

Vicon Industries, Inc. designs, develops, assembles, and markets video management systems and system components for use in security, surveillance, safety, and communication applications worldwide. Its product line comprises various video and access control system elements, including cameras for image capture and stand-alone network video management system software, as well as various video recording, storage, management, output devices, and door controllers and peripherals; analog, digital, and high definition megapixel cameras for fixed and robotic positioning applications; and other video system components, such as video encoders decoders and monitors, camera lenses, housings and mounts, matrix video switchers and controls, and various video transmission devices. The company's access control system comprises electronic door controllers and communication panels, which is managed by network access control software. Its products are used by commercial and industrial users comprising office buildings, manufacturing plants, warehouses, apartment complexes, shopping malls, and retail stores; federal, state, and local governments for national security purposes, agency facilities, prisons, and military installations; and financial institutions that include banks, clearing houses, brokerage firms, and depositories for security purposes. The company's products are also used by transportation departments for highway traffic control, and bridge and tunnel monitoring, as well as airport, subway, bus, and seaport security and surveillance; gaming casinos; health care facilities, which comprise hospitals; and institutions of education, such as schools and universities, as well as hotels and sports arenas. It sells its products primarily to independent dealers, system integrators, and security products distributors. The company was founded in 1967 and is headquartered in Hauppauge, New York.

Full VCON Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VCON vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VCON vs SCHDVCON vs JEPIVCON vs OVCON vs KOVCON vs MAINVCON vs JNJVCON vs MRKVCON vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.